Navigation Links
Stem Cell Technology Offers Promise of Huge Savings for Drug Developers
Date:3/19/2008

NEW YORK, March 19 /PRNewswire/ -- More than 90% of drugs entering clinical development fail to get to market, due to the lack of effectiveness or adverse side effects not detected in animal tests. These false positives could be avoided with pre-clinical tests using stem cell technologies, potentially saving drug developers millions, according to Kalorama Information's new report Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development

The discovery and commercialization of a new drug costs in excess of $1 billion and requires more than 14 years. Early toxicity testing is a particular problem, since there are currently no good models for determining whether a drug will be toxic in humans. Some unsafe products advance through testing and approval, only to be pulled from the market later at a huge expense, as was the case with Vioxx and Bextra.

Though stem cell-based drug development technologies are in an early stage of development, and will most likely not become available before 2012 at the earliest, their prospects are promising.

"The excitement around stem cells has understandably been in the potential for therapy, but drug development is where they may have the most impact on healthcare," notes Bruce Carlson, publisher of Kalorama Information. "Stem cell technology could provide a virtually endless supply of liver or heart cells for testing, saving developers tens, if not hundreds of millions of dollars in direct testing fees, as well as indirect costs related to drug recalls."

Recognizing stem cells' potential, GlaxoSmithKline, AstraZeneca and Roche established a new venture in 2007, Stem Cells for Safer Medicines Ltd., to develop effective ways of using human ES cells to screen for potentially dangerous side effects of new drugs before they go into clinical trials.

Kalorama Information's report Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development discusses critical issues and trends in this exciting new field. The information and forecasts presented through 2020 were gathered through secondary research and interviews conducted with industry executives. The report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Stem-Cells-Worldwide-1597988/.

About Kalorama Information

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. For more information, contact Andrea Hiller at 212-807-2673 or press@kaloramainformation.com, or visit http://www.kaloramaInformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
2. New England Technology Foundation Announces Connecting for Childrens Charities 2008 Event
3. Healthcare Tech and the World: Personalized Technology to Benefit Healthcare Consumers in the Future
4. RIVAs Cutting Edge Technology To Help Intermountain Healthcare Enhance Medication Delivery Safety
5. New Technology No Better at Spotting Anesthesia Awareness
6. Virtual reality and computer technology improve stroke rehabilitation
7. Advanced Technology in Dental Imaging Benefits Patients
8. Precyse Solutions Promotes Ken Lacy to Senior Vice President & CIO to Drive Advancement of PrecyseNet(TM), Precyses Advanced Technology Solution
9. Vendormate Again Selected as Top 40 Georgia Innovative Technology Company
10. Breakthrough Seating Technology, ergoSEET(TM), Now Available in Indianapolis
11. Hill-Rom Selects NanoHorizons to Provide Antimicrobial Protection for Hill-Rom Products Using Nanotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... , ... August 18, 2017 , ... ... financial planning assistance that serves communities throughout southern Florida, is working to support ... scholarship assets to children from low income families. , The Take Stock In ...
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 active patients, ... replacement therapy and integrative medicine, has become a frontrunner for people seeking help ... menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in 2003 by ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Our Mountains to Climb: A ... a couple that grew stronger together through the faith they shared to overcome struggles ... is the creation of published author, Barbara J. Corcoran, a retired teacher and happily ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... marketers of high-quality anti-aging skincare solutions, recently announced the launch of ... products are an affordable, yet effective alternative to expensive plastic surgery or in-patient ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... a new location in Goldsboro, NC to its family of practices. Residents of ... Associates’ trademark starting August 15, 2017. , Riccobene Associates Family Dentistry, founded ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... 31, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), has been ... Michigan by Crain,s Detroit Business . ... companies by three-year revenue growth. This year,s edition measures growth ... To view the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... incredible triumph," said Phil Hagerman , CEO and chairman ...
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
(Date:7/27/2017)... Services, Inc. (NYSE: WST ) today announced ... financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record high, ... constant currency (organic) grew by 3.9%. ... in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS ...
Breaking Medicine Technology: